glucagon agonist retatrutide triple gip glp-1 phase 3 2025 Dual and Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Triple hormone receptor agonist retatrutide

First: plan for long-term, possibly lifelong therapy

Heres what you need to know before you buy

Whether you are managing oxidative stress, supporting skin health, or enhancing your detox routine, REVIVs Glutathione IM therapy offers a clinical-grade solution rooted in wellness science

EmFace lifts and tightens skin to help you achieve a younger-looking appearance

ZepBound, launched for obesity in late 2023, quickly added hundreds of millions in sales by mid-2025, its global sales were already in the hundreds of millions as clinics rolled out the new weight-loss injection

First, SELECT was designed as a CV outcomes trial and not a weight-loss trial, and weight loss was only a supportive secondary endpoint in the trial design